FDA Grants Fast Track Designation for Amicus Therapeutics ' Migalastat for Treatment of Fabry Disease

CRANBURY, N.J., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the oral precision medicine migalastat for the treatment of...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news